Real-World Impact of Uncontrolled Symptoms and Suboptimal Treatment Response in Patients With Crohn’s Disease in the United States and Europe
Open Access
- 29 November 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 7 (1) , otae074
Abstract
Background: Despite a wide range of available treatments, there is limited evidence as to why significant numbers of Crohn’s disease (CD) patients do not achieve disease remission or continue to have residual symptom burden. We aimed to quantify the impact of this suboptimal treatment on patient symptom incidence and severity, quality of life (QoL), and work impairment. Methods: Data were derived from the Adelphi Real World CD Disease Specific Programme, a cross-sectional survey of CD patients and their treating physicians in France, Germany, Italy, Spain, the United Kingdom, and the United States between January 2020 and March 2021. Physicians reported on patients’ clinical history, disease status, symptom load, and treatment. Patients reported their QoL and activity impairment using the EQ-5D-5L and Work Productivity and Activity Impairment measures. Patients were divided into remitters, partial remitters, and non-remitters. Multivariate regression models were used to assess the impact of remission status on clinical and QoL outcomes. Results: Of 1786 patients, 24.1% were remitters, 53.2% were partial remitters, and 22.7% were non-remitters. Partial remitters and non-remitters had a significantly higher symptom load than remitters (P < .05), and non-remitters were up to 15 times more likely to experience key symptoms than remitters. Both non-remitters and partial remitters were also significantly more likely to have increased symptom severity (P < .05). Non-remitters were more likely to have switched treatment and received more treatment lines, as well as having significantly worse QoL, than remitters. Conclusions: Suboptimal treatment response was associated with increased symptoms and QoL burden. Despite the increased burden experienced, partial remitters were not more likely to switch or receive more treatment lines than remitters, demonstrating the need to initiate effective therapy.Keywords
Funding Information
- Janssen Global Services, LLC
This publication has 45 references indexed in Scilit:
- The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current EvidenceAdvances in Therapy, 2020
- Histologic Healing Is More Strongly Associated with Clinical Outcomes in Ileal Crohn’s Disease than Endoscopic HealingClinical Gastroenterology and Hepatology, 2019
- A comprehensive review and update on Crohn's diseaseDisease-a-Month, 2018
- Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with VedolizumabDigestive Diseases and Sciences, 2017
- Systematic review: Histological remission in inflammatory bowel disease. Is ‘complete’ remission the new treatment paradigm? An IOIBD initiativeJournal of Crohn's and Colitis, 2014
- Clinical implications of mucosal healing in the management of patients with inflammatory bowel diseaseDigestive and Liver Disease, 2013
- Correlation Between the Crohn's Disease Activity and Harvey–Bradshaw Indices in Assessing Crohn's Disease SeverityClinical Gastroenterology and Hepatology, 2010
- Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohnʼs diseaseInflammatory Bowel Diseases, 2009
- Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's diseaseClinical Therapeutics, 2008
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990